CN106361884A - 无糖型消银颗粒及其质量检测方法 - Google Patents
无糖型消银颗粒及其质量检测方法 Download PDFInfo
- Publication number
- CN106361884A CN106361884A CN201611090054.7A CN201611090054A CN106361884A CN 106361884 A CN106361884 A CN 106361884A CN 201611090054 A CN201611090054 A CN 201611090054A CN 106361884 A CN106361884 A CN 106361884A
- Authority
- CN
- China
- Prior art keywords
- solution
- parts
- radix
- sucrose
- reference substance
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008187 granular material Substances 0.000 title claims abstract description 48
- 201000004681 Psoriasis Diseases 0.000 title abstract description 12
- 238000001514 detection method Methods 0.000 title abstract description 4
- 238000000034 method Methods 0.000 claims abstract description 25
- 239000003814 drug Substances 0.000 claims abstract description 19
- XOJVHLIYNSOZOO-SWOBOCGESA-N Arctiin Chemical compound C1=C(OC)C(OC)=CC=C1C[C@@H]1[C@@H](CC=2C=C(OC)C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)=CC=2)C(=O)OC1 XOJVHLIYNSOZOO-SWOBOCGESA-N 0.000 claims abstract description 17
- 239000000463 material Substances 0.000 claims abstract description 11
- 239000000796 flavoring agent Substances 0.000 claims abstract description 10
- 235000013355 food flavoring agent Nutrition 0.000 claims abstract description 8
- 239000000243 solution Substances 0.000 claims description 73
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 72
- 238000012360 testing method Methods 0.000 claims description 50
- 241000628997 Flos Species 0.000 claims description 49
- 239000013558 reference substance Substances 0.000 claims description 37
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 36
- 239000000843 powder Substances 0.000 claims description 33
- 238000001914 filtration Methods 0.000 claims description 29
- 239000009509 xiaoyin Substances 0.000 claims description 27
- 229960004756 ethanol Drugs 0.000 claims description 26
- 239000000047 product Substances 0.000 claims description 21
- CRDNMYFJWFXOCH-YPKPFQOOSA-N (3z)-3-(3-oxo-1h-indol-2-ylidene)-1h-indol-2-one Chemical compound N/1C2=CC=CC=C2C(=O)C\1=C1/C2=CC=CC=C2NC1=O CRDNMYFJWFXOCH-YPKPFQOOSA-N 0.000 claims description 18
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 18
- 239000000706 filtrate Substances 0.000 claims description 18
- 238000004809 thin layer chromatography Methods 0.000 claims description 18
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 claims description 17
- ZSBXGIUJOOQZMP-UHFFFAOYSA-N Isomatrine Natural products C1CCC2CN3C(=O)CCCC3C3C2N1CCC3 ZSBXGIUJOOQZMP-UHFFFAOYSA-N 0.000 claims description 16
- ZSBXGIUJOOQZMP-JLNYLFASSA-N Matrine Chemical compound C1CC[C@H]2CN3C(=O)CCC[C@@H]3[C@@H]3[C@H]2N1CCC3 ZSBXGIUJOOQZMP-JLNYLFASSA-N 0.000 claims description 16
- 239000007788 liquid Substances 0.000 claims description 16
- 229930014456 matrine Natural products 0.000 claims description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 15
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical class CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims description 14
- 239000002904 solvent Substances 0.000 claims description 14
- 238000000605 extraction Methods 0.000 claims description 13
- 239000000203 mixture Substances 0.000 claims description 13
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 12
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 12
- 239000000741 silica gel Substances 0.000 claims description 12
- 229910002027 silica gel Inorganic materials 0.000 claims description 12
- 229940079593 drug Drugs 0.000 claims description 11
- 238000010992 reflux Methods 0.000 claims description 10
- CRDNMYFJWFXOCH-BUHFOSPRSA-N Couroupitine B Natural products N\1C2=CC=CC=C2C(=O)C/1=C1/C2=CC=CC=C2NC1=O CRDNMYFJWFXOCH-BUHFOSPRSA-N 0.000 claims description 9
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 9
- CRDNMYFJWFXOCH-UHFFFAOYSA-N isoindigotin Natural products N1C2=CC=CC=C2C(=O)C1=C1C2=CC=CC=C2NC1=O CRDNMYFJWFXOCH-UHFFFAOYSA-N 0.000 claims description 9
- 239000007921 spray Substances 0.000 claims description 9
- 239000002671 adjuvant Substances 0.000 claims description 8
- 238000001035 drying Methods 0.000 claims description 8
- 229910021529 ammonia Inorganic materials 0.000 claims description 7
- 235000009508 confectionery Nutrition 0.000 claims description 7
- 238000007598 dipping method Methods 0.000 claims description 7
- 239000000284 extract Substances 0.000 claims description 7
- CWVRJTMFETXNAD-FWCWNIRPSA-N 3-O-Caffeoylquinic acid Natural products O[C@H]1[C@@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-FWCWNIRPSA-N 0.000 claims description 6
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 6
- PZIRUHCJZBGLDY-UHFFFAOYSA-N Caffeoylquinic acid Natural products CC(CCC(=O)C(C)C1C(=O)CC2C3CC(O)C4CC(O)CCC4(C)C3CCC12C)C(=O)O PZIRUHCJZBGLDY-UHFFFAOYSA-N 0.000 claims description 6
- CWVRJTMFETXNAD-KLZCAUPSSA-N Neochlorogenin-saeure Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O CWVRJTMFETXNAD-KLZCAUPSSA-N 0.000 claims description 6
- YKRGDOXKVOZESV-WRJNSLSBSA-N Paeoniflorin Chemical compound C([C@]12[C@H]3O[C@]4(O)C[C@](O3)([C@]1(C[C@@H]42)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)C)OC(=O)C1=CC=CC=C1 YKRGDOXKVOZESV-WRJNSLSBSA-N 0.000 claims description 6
- CWVRJTMFETXNAD-JUHZACGLSA-N chlorogenic acid Chemical compound O[C@@H]1[C@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-JUHZACGLSA-N 0.000 claims description 6
- 229940074393 chlorogenic acid Drugs 0.000 claims description 6
- FFQSDFBBSXGVKF-KHSQJDLVSA-N chlorogenic acid Natural products O[C@@H]1C[C@](O)(C[C@@H](CC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O FFQSDFBBSXGVKF-KHSQJDLVSA-N 0.000 claims description 6
- 235000001368 chlorogenic acid Nutrition 0.000 claims description 6
- BMRSEYFENKXDIS-KLZCAUPSSA-N cis-3-O-p-coumaroylquinic acid Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)cc2)[C@@H]1O)C(=O)O BMRSEYFENKXDIS-KLZCAUPSSA-N 0.000 claims description 6
- 229960000935 dehydrated alcohol Drugs 0.000 claims description 6
- 229920006395 saturated elastomer Polymers 0.000 claims description 6
- ONBIUAZBGHXJDM-UHFFFAOYSA-J bismuth;potassium;tetraiodide Chemical compound [K+].[I-].[I-].[I-].[I-].[Bi+3] ONBIUAZBGHXJDM-UHFFFAOYSA-J 0.000 claims description 5
- 238000001816 cooling Methods 0.000 claims description 5
- WBZFUFAFFUEMEI-UHFFFAOYSA-M Acesulfame k Chemical compound [K+].CC1=CC(=O)[N-]S(=O)(=O)O1 WBZFUFAFFUEMEI-UHFFFAOYSA-M 0.000 claims description 4
- 108010011485 Aspartame Proteins 0.000 claims description 4
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 4
- 229930195725 Mannitol Natural products 0.000 claims description 4
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 4
- 229920002472 Starch Polymers 0.000 claims description 4
- UEDUENGHJMELGK-HYDKPPNVSA-N Stevioside Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UEDUENGHJMELGK-HYDKPPNVSA-N 0.000 claims description 4
- 235000010358 acesulfame potassium Nutrition 0.000 claims description 4
- 229960004998 acesulfame potassium Drugs 0.000 claims description 4
- 239000000619 acesulfame-K Substances 0.000 claims description 4
- 239000000605 aspartame Substances 0.000 claims description 4
- 235000010357 aspartame Nutrition 0.000 claims description 4
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 claims description 4
- 229960003438 aspartame Drugs 0.000 claims description 4
- 238000010438 heat treatment Methods 0.000 claims description 4
- 239000008101 lactose Substances 0.000 claims description 4
- 239000000594 mannitol Substances 0.000 claims description 4
- 235000010355 mannitol Nutrition 0.000 claims description 4
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 4
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 4
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 4
- 239000008107 starch Substances 0.000 claims description 4
- 235000019698 starch Nutrition 0.000 claims description 4
- 229940013618 stevioside Drugs 0.000 claims description 4
- OHHNJQXIOPOJSC-UHFFFAOYSA-N stevioside Natural products CC1(CCCC2(C)C3(C)CCC4(CC3(CCC12C)CC4=C)OC5OC(CO)C(O)C(O)C5OC6OC(CO)C(O)C(O)C6O)C(=O)OC7OC(CO)C(O)C(O)C7O OHHNJQXIOPOJSC-UHFFFAOYSA-N 0.000 claims description 4
- 235000019202 steviosides Nutrition 0.000 claims description 4
- 239000012085 test solution Substances 0.000 claims description 4
- JMUFJNCIWRHXIR-UHFFFAOYSA-N O.OC.OC=O.CCOC(C)=O Chemical compound O.OC.OC=O.CCOC(C)=O JMUFJNCIWRHXIR-UHFFFAOYSA-N 0.000 claims description 3
- 239000004952 Polyamide Substances 0.000 claims description 3
- 238000010521 absorption reaction Methods 0.000 claims description 3
- PQLVXDKIJBQVDF-UHFFFAOYSA-N acetic acid;hydrate Chemical compound O.CC(O)=O PQLVXDKIJBQVDF-UHFFFAOYSA-N 0.000 claims description 3
- 239000002390 adhesive tape Substances 0.000 claims description 3
- JZPPLVLVJKSTNB-UHFFFAOYSA-N benzene;methanol;propan-2-one Chemical compound OC.CC(C)=O.C1=CC=CC=C1 JZPPLVLVJKSTNB-UHFFFAOYSA-N 0.000 claims description 3
- 150000001720 carbohydrates Chemical class 0.000 claims description 3
- 238000005660 chlorination reaction Methods 0.000 claims description 3
- 238000012850 discrimination method Methods 0.000 claims description 3
- 238000003810 ethyl acetate extraction Methods 0.000 claims description 3
- 239000011521 glass Substances 0.000 claims description 3
- 238000005259 measurement Methods 0.000 claims description 3
- 229920002647 polyamide Polymers 0.000 claims description 3
- QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid Substances OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 2
- 240000000774 Cunila origanoides Species 0.000 claims 2
- 235000018274 Cunila origanoides Nutrition 0.000 claims 2
- 235000014866 Dictamnus albus Nutrition 0.000 claims 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims 1
- IBPFZCOJYVDKGN-UHFFFAOYSA-N OC.OC=O.ClC(Cl)Cl.CCOC(C)=O Chemical compound OC.OC=O.ClC(Cl)Cl.CCOC(C)=O IBPFZCOJYVDKGN-UHFFFAOYSA-N 0.000 claims 1
- YPQJHZKJHIBJAP-UHFFFAOYSA-N [K].[Bi] Chemical compound [K].[Bi] YPQJHZKJHIBJAP-UHFFFAOYSA-N 0.000 claims 1
- 239000002021 butanolic extract Substances 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- HEBKCHPVOIAQTA-NGQZWQHPSA-N d-xylitol Chemical compound OC[C@H](O)C(O)[C@H](O)CO HEBKCHPVOIAQTA-NGQZWQHPSA-N 0.000 claims 1
- 235000012907 honey Nutrition 0.000 claims 1
- 229910052740 iodine Inorganic materials 0.000 claims 1
- 239000011630 iodine Substances 0.000 claims 1
- -1 reflux Substances 0.000 claims 1
- 238000005406 washing Methods 0.000 claims 1
- 201000001421 hyperglycemia Diseases 0.000 abstract description 8
- 208000031226 Hyperlipidaemia Diseases 0.000 abstract description 7
- 229930006000 Sucrose Natural products 0.000 abstract description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 abstract description 4
- 239000005720 sucrose Substances 0.000 abstract description 4
- 238000002360 preparation method Methods 0.000 abstract description 3
- 241000382455 Angelica sinensis Species 0.000 abstract 1
- 241000205585 Aquilegia canadensis Species 0.000 abstract 1
- 244000020518 Carthamus tinctorius Species 0.000 abstract 1
- 235000003255 Carthamus tinctorius Nutrition 0.000 abstract 1
- 241000931705 Cicada Species 0.000 abstract 1
- 244000170916 Paeonia officinalis Species 0.000 abstract 1
- 235000006484 Paeonia officinalis Nutrition 0.000 abstract 1
- 239000008280 blood Substances 0.000 description 11
- 210000004369 blood Anatomy 0.000 description 11
- 208000003251 Pruritus Diseases 0.000 description 7
- 230000000694 effects Effects 0.000 description 6
- 208000002193 Pain Diseases 0.000 description 5
- 229940109275 cyclamate Drugs 0.000 description 5
- HCAJEUSONLESMK-UHFFFAOYSA-N cyclohexylsulfamic acid Chemical compound OS(=O)(=O)NC1CCCCC1 HCAJEUSONLESMK-UHFFFAOYSA-N 0.000 description 5
- 210000004072 lung Anatomy 0.000 description 5
- 230000008961 swelling Effects 0.000 description 5
- 206010037660 Pyrexia Diseases 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 201000005404 rubella Diseases 0.000 description 4
- 210000002784 stomach Anatomy 0.000 description 4
- 208000006820 Arthralgia Diseases 0.000 description 3
- 206010010774 Constipation Diseases 0.000 description 3
- 201000004624 Dermatitis Diseases 0.000 description 3
- 208000015220 Febrile disease Diseases 0.000 description 3
- 206010023126 Jaundice Diseases 0.000 description 3
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 3
- 208000010668 atopic eczema Diseases 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 231100000614 poison Toxicity 0.000 description 3
- 230000001185 psoriatic effect Effects 0.000 description 3
- 206010037844 rash Diseases 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 208000011580 syndromic disease Diseases 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- 239000000811 xylitol Substances 0.000 description 3
- 235000010447 xylitol Nutrition 0.000 description 3
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 3
- 229960002675 xylitol Drugs 0.000 description 3
- 206010063409 Acarodermatitis Diseases 0.000 description 2
- 201000000736 Amenorrhea Diseases 0.000 description 2
- 206010001928 Amenorrhoea Diseases 0.000 description 2
- 206010007247 Carbuncle Diseases 0.000 description 2
- 206010010904 Convulsion Diseases 0.000 description 2
- 206010011224 Cough Diseases 0.000 description 2
- 208000005171 Dysmenorrhea Diseases 0.000 description 2
- 206010013935 Dysmenorrhoea Diseases 0.000 description 2
- 208000010201 Exanthema Diseases 0.000 description 2
- 201000005505 Measles Diseases 0.000 description 2
- 206010068319 Oropharyngeal pain Diseases 0.000 description 2
- 201000007100 Pharyngitis Diseases 0.000 description 2
- 241000447727 Scabies Species 0.000 description 2
- 206010043376 Tetanus Diseases 0.000 description 2
- 206010043458 Thirst Diseases 0.000 description 2
- 206010044565 Tremor Diseases 0.000 description 2
- 208000025865 Ulcer Diseases 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 210000001015 abdomen Anatomy 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 230000006978 adaptation Effects 0.000 description 2
- 239000003513 alkali Substances 0.000 description 2
- 231100000540 amenorrhea Toxicity 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 230000036461 convulsion Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 208000001848 dysentery Diseases 0.000 description 2
- 201000005884 exanthem Diseases 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N formic acid Substances OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 201000007227 lymph node tuberculosis Diseases 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 208000005687 scabies Diseases 0.000 description 2
- 208000017520 skin disease Diseases 0.000 description 2
- 239000002893 slag Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 239000003440 toxic substance Substances 0.000 description 2
- 231100000397 ulcer Toxicity 0.000 description 2
- MCSXGCZMEPXKIW-UHFFFAOYSA-N 3-hydroxy-4-[(4-methyl-2-nitrophenyl)diazenyl]-N-(3-nitrophenyl)naphthalene-2-carboxamide Chemical compound Cc1ccc(N=Nc2c(O)c(cc3ccccc23)C(=O)Nc2cccc(c2)[N+]([O-])=O)c(c1)[N+]([O-])=O MCSXGCZMEPXKIW-UHFFFAOYSA-N 0.000 description 1
- 206010000077 Abdominal mass Diseases 0.000 description 1
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- 208000004429 Bacillary Dysentery Diseases 0.000 description 1
- 208000002177 Cataract Diseases 0.000 description 1
- 206010007882 Cellulitis Diseases 0.000 description 1
- 206010013952 Dysphonia Diseases 0.000 description 1
- 201000000297 Erysipelas Diseases 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 208000005577 Gastroenteritis Diseases 0.000 description 1
- 206010017915 Gastroenteritis shigella Diseases 0.000 description 1
- 208000037319 Hepatitis infectious Diseases 0.000 description 1
- 208000010473 Hoarseness Diseases 0.000 description 1
- 206010021118 Hypotonia Diseases 0.000 description 1
- 206010024229 Leprosy Diseases 0.000 description 1
- 206010025421 Macule Diseases 0.000 description 1
- 208000019255 Menstrual disease Diseases 0.000 description 1
- 206010027514 Metrorrhagia Diseases 0.000 description 1
- 208000005647 Mumps Diseases 0.000 description 1
- 208000007101 Muscle Cramp Diseases 0.000 description 1
- 241000475481 Nebula Species 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 208000004680 Rectal Fistula Diseases 0.000 description 1
- 206010067868 Skin mass Diseases 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 206010042674 Swelling Diseases 0.000 description 1
- 206010047799 Vulvovaginitis trichomonal Diseases 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 208000012873 acute gastroenteritis Diseases 0.000 description 1
- 206010002156 anal fistula Diseases 0.000 description 1
- 208000002399 aphthous stomatitis Diseases 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- 239000000812 cholinergic antagonist Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 208000001780 epistaxis Diseases 0.000 description 1
- 230000008029 eradication Effects 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 239000003172 expectorant agent Substances 0.000 description 1
- 230000003419 expectorant effect Effects 0.000 description 1
- 208000017561 flaccidity Diseases 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 208000035861 hematochezia Diseases 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 208000005252 hepatitis A Diseases 0.000 description 1
- 230000003516 hyperlipidaemic effect Effects 0.000 description 1
- 210000003026 hypopharynx Anatomy 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 229960001375 lactose Drugs 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 210000000867 larynx Anatomy 0.000 description 1
- 235000004213 low-fat Nutrition 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 229960001855 mannitol Drugs 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 230000002175 menstrual effect Effects 0.000 description 1
- 208000010805 mumps infectious disease Diseases 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 231100000862 numbness Toxicity 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 208000028280 polygenic inheritance Diseases 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000001047 pyretic effect Effects 0.000 description 1
- 238000012372 quality testing Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 201000005113 shigellosis Diseases 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 206010040882 skin lesion Diseases 0.000 description 1
- 231100000444 skin lesion Toxicity 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 230000002048 spasmolytic effect Effects 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 229940032147 starch Drugs 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 230000008736 traumatic injury Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 210000003905 vulva Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/80—Scrophulariaceae (Figwort family)
- A61K36/808—Scrophularia (figwort)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/63—Arthropods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/19—Acanthaceae (Acanthus family)
- A61K36/195—Strobilanthes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/232—Angelica
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/238—Saposhnikovia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/286—Carthamus (distaff thistle)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/31—Brassicaceae or Cruciferae (Mustard family), e.g. broccoli, cabbage or kohlrabi
- A61K36/315—Isatis, e.g. Dyer's woad
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/35—Caprifoliaceae (Honeysuckle family)
- A61K36/355—Lonicera (honeysuckle)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/489—Sophora, e.g. necklacepod or mamani
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/65—Paeoniaceae (Peony family), e.g. Chinese peony
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
- A61K36/704—Polygonum, e.g. knotweed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/80—Scrophulariaceae (Figwort family)
- A61K36/804—Rehmannia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/85—Verbenaceae (Verbena family)
- A61K36/855—Clerodendrum, e.g. glorybower
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/90—Plate chromatography, e.g. thin layer or paper chromatography
- G01N30/94—Development
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Botany (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Insects & Arthropods (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明涉及中药技术领域,尤其涉及一种无糖型消银颗粒及其质量检测方法。目前上市的消银颗粒采用了大量蔗糖作为辅料,限制了高血糖、高血脂等人群用药选择,制约了该产品的推广应用。本发明提供一种无糖型消银颗粒,由如下重量份的原料药组成:地黄182,牡丹皮92,赤芍92,当归92,苦参92,金银花92,玄参92,牛蒡子92,蝉蜕46,白鲜皮92,防风46,大青叶92,红花46,无糖型辅料450~600,非糖调味剂;按照如下方法制备成无糖型颗粒。本发明为无糖制剂,分散性、防潮性好,同时适合高血糖、高血脂等银屑病患者服用,为高血糖、高血脂等银屑病患者提供方便。本发明还提供一种无糖型消银颗粒的质量检测方法。
Description
技术领域
本发明涉及中药技术领域,尤其涉及一种无糖型消银颗粒及其质量检测方法。
背景技术
银屑病又称牛皮癣,典型临床表现为鳞屑性红斑或斑块,局限或广泛分布。是一种由多基因遗传决定的、多环境因素刺激诱导的免疫异常性慢性增生性皮肤病,是临床常见慢性、反复性及终身性皮肤病,病情较顽固,严重影响患者身心健康及生活质量。银屑病发病率占世界人口的0.1%-3%,目前全球已有银屑病患者1.25亿。我国总患病率为0.72%,目前已有1000万患者。
银屑病治疗目的是防止每次发作,尽可能地延长其缓解时间。治疗必须根据具体情况进行选择,最重要的是要因不同的临床类型、分期、皮损的严重程度及部位而异。避免各种可能的诱因。急性期应避免刺激疗法如强烈的外用药物和紫外线照射,防止外伤,忌搔抓及热水烫洗。轻者以外用药物为主,重者可根据病情选用全身治疗。选择治疗时应权衡利弊,并需密切观测不良反应。病情控制后应坚持巩固治疗,避免突然停用药物。西医治疗银屑病的起效较快,但目前还没有彻底根除治疗的特效治疗药物,而且西药毒副作用较大,经济成本较高,不宜长期使用。
近年来由于环境、饮食、工作压力等因素的影响,患高血糖、高血脂等的人群呈逐年上升趋势,他们对饮食、用药等方面均要求低蔗糖、低脂肪等,而目前上市的消银颗粒采用了大量蔗糖作为辅料,限制了高血糖、高血脂等人群用药选择,制约了该产品的推广应用。
发明内容
为克服相关技术中存在的问题,本公开提供一种无糖型消银颗粒及其质量检测方法。
根据本发明提供一种无糖型消银颗粒,所述无糖型消银颗粒由如下重量份的原料药组成:地黄182,牡丹皮92,赤芍92,当归92,苦参92,金银花92,玄参92,牛蒡子92,蝉蜕46,白鲜皮92,防风46,大青叶92,红花46,无糖型辅料450~600,非糖调味剂;按照如下方法制备成无糖型颗粒:
将金银花、红花粉碎成细粉;地黄、牡丹皮、赤芍、当归、苦参、玄参、牛蒡子、蝉蜕、白鲜皮、防风和大青叶酌予碎断,加七倍量70%乙醇浸渍12小时,滤过,再加70%乙醇,回流提取12小时,滤过,合并提取液,回收乙醇至无醇味,浓缩成稠膏,加入金银花、红花细粉,混匀,低温干燥,粉碎成细粉,加辅料、调味剂,混匀,制成颗粒,干燥。
可选地,所述无糖型辅料包括淀粉、木糖醇、微晶纤维素、乳糖或者甘露醇。
可选地,所述调味剂包括安赛蜜、甜蜜素、阿斯巴甜或者甜菊苷。
一种无糖型消银颗粒的质量检测方法,鉴别方法包括以下项目的部分或全部:
(1):取本品10g,研磨成粉末,加入40ml氯仿,加热回流20分钟,放置冷却后过滤,滤液浓缩至1ml,作为供试品溶液;另取靛玉红、苦参碱对照品,分别加氯仿制成每1ml各含1mg的靛玉红、苦参碱溶液,作为对照品溶液;对照薄层色谱法试验,吸取供试品溶液10~20μL、对照品溶液各5μL,分别点于同一硅胶G薄层板上,以苯-丙酮-甲醇的比例为8:3:0.5为展开剂,在氨蒸气饱和的展开缸内展开,取出后晾干;供试品色谱中,在与靛玉红对照品色谱相应的位置上,显相同颜色的斑点;再喷以改良碘化铋钾溶液,供试品色谱中,在与苦参碱对照品色谱相应的位置上,显示相同颜色的斑点;
(2):取本品10g,研磨成粉末,加入40ml乙醇,超声处理30分钟,过滤后将滤液蒸干,加入15ml水使残渣溶解,过滤,滤液用乙醚提取2次,每次15ml,弃去乙醚液,用水饱和正丁醇提取3次,每次15ml,合并正丁醇液,蒸干,加入1ml乙醇使残渣溶解,作为供试品溶液;另取芍药苷对照品,加乙醇制成每1ml含1mg的芍药苷溶液,作为对照品溶液;对照薄层色谱法试验,吸取上述两种溶液各5~10μL,分别点于同一硅胶G薄层板上,以氯仿-醋酸乙酯-甲醇-甲酸比例为40:5:10:0.2为展开剂展开,取出后晾干,喷以5%香草醛硫酸溶液,热风吹至斑点显色清晰;供试品色谱中,在与对照色谱相应的位置上,显相同颜色的斑点;
(3)取本品5g,研磨成粉末,加入12ml丙酮、3ml水,振摇5分钟,浸泡5分钟,过滤后滤液作为供试品溶液;另取红花对照药材0.2g,同法制成对照药材溶液;对照薄层色谱法试验,吸取上述两种溶液各5μL,分别点于同一硅胶G薄层板上,以醋酸乙酯-甲酸-水-甲醇比例为7:2:3:0.3为展开剂展开,取出后晾干;供试品色谱中,在与对照药材色谱相应的位置上,显相同的红色斑点;
(4):取本品10g,加入40ml乙醇,加热回流1小时,过滤后滤液蒸干,加入5ml水使残渣溶解,浸泡30分钟,过滤后滤液分别用10ml和5ml醋酸乙酯提取2次,合并醋酸乙酯液,蒸干,加入1ml甲醇使滤渣溶解,作为供试品溶液;另取绿原酸对照品,加甲醇制成每1ml含0.5mg的绿原酸溶液,作为对照品溶液;对照薄层色谱法试验,吸取上述两种溶液各1μL,分别点于同一聚酰胺薄膜上,以冰醋酸-水比例为1:2为展开剂展开,取出后晾干,置于365nm的紫外灯下检视;供试品色谱中,在与对照品色谱相应的位置上,显相同颜色的荧光斑点。
可选地,苦参碱的含量测定方法为:
取本品装量差异项下的内容物,研磨成粉末,取7g,精密称定,置于有塞的锥形瓶中,加入50ml氯仿,5ml浓氨试液,水浴加热回流1小时,冷却后分取氯仿液,加入氯仿30ml于残渣中,加热回流2次,每次30分钟,合并氯仿液,回收氯仿,残渣用无水乙醇分次溶解、洗涤,定量转移至5ml量瓶中,稀释至刻度,摇匀,作为供试品溶液;另取苦参碱对照品适量,精密称定,加无水乙醇制成每1ml含1mg苦参碱的溶液,作为对照品溶液;对照薄层色谱法试验,精密吸取上述两种溶液各4μL,分别交叉点于同一硅胶G薄层板上,以环己烷-氯仿-甲醇-浓氨试液比例为25:50:6:2的下层溶液为展开剂,在氨蒸气饱和下展开,取出后晾干,喷涂稀碘化铋钾试液,在薄层板上覆盖同样大小的玻璃板,周围用胶布固定,放置60分钟,对照薄层色谱法进行扫描,波长:λs=500nm,λR=650nm,测量供试品吸收度积分值与对照品吸收度积分值,计算结果;
本品每袋含苦参以苦参碱(C15H24N2O)计,不得少于2.1mg。
本发明采用的原料药的性味、药理及作用如下:
地黄:性味、归经:甘,微温。归心、肝、肾经。补血滋阴,益精填髓。
牡丹皮:苦、辛,微寒,归心、肝、肾经,具有清热凉血、活血化淤、退虚热等功效。
赤芍:苦,微寒。归肝经。有清热凉血,活血祛瘀的功效。
当归:味甘;辛;苦;性温;主治血虚诸证;月经不调;经闭;痛经;症瘕结聚;崩漏;虚寒腹痛;痿痹;肌肤麻木;肠燥便难;赤痢后重;痈疽疮疡;跌扑损伤。
苦参:味苦;性寒。用于热痢,便血,黄疸尿闭,赤白带下,阴肿阴痒,湿疹,湿疮,皮肤瘙痒,疥癣麻风;外治滴虫性阴道炎。
金银花:甘,微苦,清香,辛,寒。归肺,胃,心,大肠经。治温病发热,热毒血痢,痈疡,肿毒,瘰疬,痔漏。
玄参:味甘、苦、咸;性微寒。归肺,胃,肾经。主治温热病热和营血、身热、烦渴、舌绛、发斑、骨蒸劳嗽、虚烦不寤、津伤便秘、目涩昏花、咽喉喉肿痛、瘰疬痰核、痈疽疮毒。
牛蒡子:味辛;苦;性寒。归肺;胃经。主治风热感冒、温病初起;风热或肺热咳嗽、咯痰不畅;咽喉肿痛;斑疹不透;麻疹初期,疹出不畅及风疹瘙痒;疮疡肿毒及痄腮等。生用可润肠通便,热毒咽喉红肿疼痛,兼有热结便秘尤宜。
蝉蜕:甘,寒。归肺、肝经。散风除热,利咽,透疹,退翳,解痉。用于风热感冒,咽痛,音哑,麻疹不透,风疹瘙痒,目赤翳障,惊风抽搐,破伤风。
白鲜皮:脾经;肺经;小肠经;胃经;膀胱经。清热燥湿;祛风止痒;解毒。主治风热湿毒所致的风疹;湿疹;疥癣;黄疸;湿热痹。
防风:味辛、甘,性微温。祛风解表,胜湿止痛,止痉定搐。外感表证,风疹瘙痒,风湿痹痛,破伤风。
大青叶:味苦,大寒,无毒。清热,解毒,凉血,止血。治温病热盛烦渴,流行性感冒,急性传染性肝炎,菌痢,急性胃肠炎,急性肺炎,丹毒,吐血,衄血,黄疸,痢疾,喉痹,口疮,痈疽肿毒。
红花:性温,味辛,活血通经、散瘀止痛。用于经闭、痛经、恶露不行、症瘕痞块、跌打损伤。
本发明提供一种无糖型消银颗粒,由如下重量份的原料药组成:地黄182,牡丹皮92,赤芍92,当归92,苦参92,金银花92,玄参92,牛蒡子92,蝉蜕46,白鲜皮92,防风46,大青叶92,红花46,无糖型辅料450~600,非糖调味剂。本中药制剂为无糖制剂,分散性、防潮性好,同时适合高血糖、高血脂等银屑病患者服用,为高血糖、高血脂等银屑病患者提供方便。
应当理解的是,以上的一般描述和后文的细节描述仅是示例性和解释性的,并不能限制本发明。
具体实施方式
这里将详细地对示例性实施例进行说明。以下示例性实施例中所描述的实施方式并不代表与本发明相一致的所有实施方式。相反,它们仅是与如所附权利要求书中所详述的、本发明的一些方面相一致的方法的例子。
实施例1
一种无糖型消银颗粒,所述无糖型消银颗粒由如下重量份的原料药组成:地黄182份,牡丹皮92份,赤芍92份,当归92份,苦参92份,金银花92份,玄参92份,牛蒡子92份,蝉蜕46份,白鲜皮92份,防风46份,大青叶92份,红花46份,淀粉450份,安赛蜜适量;按照如下方法制备成无糖型颗粒:
将金银花、红花粉碎成细粉;地黄、牡丹皮、赤芍、当归、苦参、玄参、牛蒡子、蝉蜕、白鲜皮、防风和大青叶酌予碎断,加七倍量70%乙醇浸渍12小时,滤过,再加70%乙醇,回流提取12小时,滤过,合并提取液,回收乙醇至无醇味,浓缩成稠膏,加入金银花、红花细粉,混匀,低温干燥,粉碎成细粉,加450份淀粉,适量安赛蜜,混匀,制成颗粒,干燥。
实施例2
一种无糖型消银颗粒,所述无糖型消银颗粒由如下重量份的原料药组成:地黄182份,牡丹皮92份,赤芍92份,当归92份,苦参92份,金银花92份,玄参92份,牛蒡子92份,蝉蜕46份,白鲜皮92份,防风46份,大青叶92份,红花46份,木糖醇600份,甜蜜素适量;按照如下方法制备成无糖型颗粒:
将金银花、红花粉碎成细粉;地黄、牡丹皮、赤芍、当归、苦参、玄参、牛蒡子、蝉蜕、白鲜皮、防风和大青叶酌予碎断,加七倍量70%乙醇浸渍12小时,滤过,再加70%乙醇,回流提取12小时,滤过,合并提取液,回收乙醇至无醇味,浓缩成稠膏,加入金银花、红花细粉,混匀,低温干燥,粉碎成细粉,加600份木糖醇,适量甜蜜素,混匀,制成颗粒,干燥。
实施例3
一种无糖型消银颗粒,所述无糖型消银颗粒由如下重量份的原料药组成:地黄182份,牡丹皮92份,赤芍92份,当归92份,苦参92份,金银花92份,玄参92份,牛蒡子92份,蝉蜕46份,白鲜皮92份,防风46份,大青叶92份,红花46份,微晶纤维素500份,甜菊苷适量;按照如下方法制备成无糖型颗粒:
将金银花、红花粉碎成细粉;地黄、牡丹皮、赤芍、当归、苦参、玄参、牛蒡子、蝉蜕、白鲜皮、防风和大青叶酌予碎断,加七倍量70%乙醇浸渍12小时,滤过,再加70%乙醇,回流提取12小时,滤过,合并提取液,回收乙醇至无醇味,浓缩成稠膏,加入金银花、红花细粉,混匀,低温干燥,粉碎成细粉,加500份微晶纤维素,适量甜菊苷,混匀,制成颗粒,干燥。
实施例4
一种无糖型消银颗粒,所述无糖型消银颗粒由如下重量份的原料药组成:地黄182份,牡丹皮92份,赤芍92份,当归92份,苦参92份,金银花92份,玄参92份,牛蒡子92份,蝉蜕46份,白鲜皮92份,防风46份,大青叶92份,红花46份,甘露醇600份,阿斯巴甜适量;按照如下方法制备成无糖型颗粒:
将金银花、红花粉碎成细粉;地黄、牡丹皮、赤芍、当归、苦参、玄参、牛蒡子、蝉蜕、白鲜皮、防风和大青叶酌予碎断,加七倍量70%乙醇浸渍12小时,滤过,再加70%乙醇,回流提取12小时,滤过,合并提取液,回收乙醇至无醇味,浓缩成稠膏,加入金银花、红花细粉,混匀,低温干燥,粉碎成细粉,加600份甘露醇,适量阿斯巴甜,混匀,制成颗粒,干燥。
实施例5
一种无糖型消银颗粒,所述无糖型消银颗粒由如下重量份的原料药组成:地黄182份,牡丹皮92份,赤芍92份,当归92份,苦参92份,金银花92份,玄参92份,牛蒡子92份,蝉蜕46份,白鲜皮92份,防风46份,大青叶92份,红花46份,乳糖450份,甜蜜素适量;按照如下方法制备成无糖型颗粒:
将金银花、红花粉碎成细粉;地黄、牡丹皮、赤芍、当归、苦参、玄参、牛蒡子、蝉蜕、白鲜皮、防风和大青叶酌予碎断,加七倍量70%乙醇浸渍12小时,滤过,再加70%乙醇,回流提取12小时,滤过,合并提取液,回收乙醇至无醇味,浓缩成稠膏,加入金银花、红花细粉,混匀,低温干燥,粉碎成细粉,加450份乳糖,适量甜蜜素,混匀,制成颗粒,干燥。
其中以实施例3的配比为最佳实施例。
上面实施例1~6中的无糖型消银颗粒的质量检测方法,鉴别方法包括以下项目的部分或全部:
(1):取本品10g,研磨成粉末,加入40ml氯仿,加热回流20分钟,放置冷却后过滤,滤液浓缩至1ml,作为供试品溶液;另取靛玉红、苦参碱对照品,分别加氯仿制成每1ml各含1mg的靛玉红、苦参碱溶液,作为对照品溶液;对照薄层色谱法试验,吸取供试品溶液10~20μL、对照品溶液各5μL,分别点于同一硅胶G薄层板上,以苯-丙酮-甲醇的比例为8:3:0.5为展开剂,在氨蒸气饱和的展开缸内展开,取出后晾干;供试品色谱中,在与靛玉红对照品色谱相应的位置上,显相同颜色的斑点;再喷以改良碘化铋钾溶液,供试品色谱中,在与苦参碱对照品色谱相应的位置上,显示相同颜色的斑点;
(2):取本品10g,研磨成粉末,加入40ml乙醇,超声处理30分钟,过滤后将滤液蒸干,加入15ml水使残渣溶解,过滤,滤液用乙醚提取2次,每次15ml,弃去乙醚液,用水饱和正丁醇提取3次,每次15ml,合并正丁醇液,蒸干,加入1ml乙醇使残渣溶解,作为供试品溶液;另取芍药苷对照品,加乙醇制成每1ml含1mg的芍药苷溶液,作为对照品溶液;对照薄层色谱法试验,吸取上述两种溶液各5~10μL,分别点于同一硅胶G薄层板上,以氯仿-醋酸乙酯-甲醇-甲酸比例为40:5:10:0.2为展开剂展开,取出后晾干,喷以5%香草醛硫酸溶液,热风吹至斑点显色清晰;供试品色谱中,在与对照色谱相应的位置上,显相同颜色的斑点;
(3)取本品5g,研磨成粉末,加入12ml丙酮、3ml水,振摇5分钟,浸泡5分钟,过滤后滤液作为供试品溶液;另取红花对照药材0.2g,同法制成对照药材溶液;对照薄层色谱法试验,吸取上述两种溶液各5μL,分别点于同一硅胶G薄层板上,以醋酸乙酯-甲酸-水-甲醇比例为7:2:3:0.3为展开剂展开,取出后晾干;供试品色谱中,在与对照药材色谱相应的位置上,显相同的红色斑点;
(4):取本品10g,加入40ml乙醇,加热回流1小时,过滤后滤液蒸干,加入5ml水使残渣溶解,浸泡30分钟,过滤后滤液分别用10ml和5ml醋酸乙酯提取2次,合并醋酸乙酯液,蒸干,加入1ml甲醇使滤渣溶解,作为供试品溶液;另取绿原酸对照品,加甲醇制成每1ml含0.5mg的绿原酸溶液,作为对照品溶液;对照薄层色谱法试验,吸取上述两种溶液各1μL,分别点于同一聚酰胺薄膜上,以冰醋酸-水比例为1:2为展开剂展开,取出后晾干,置于365nm的紫外灯下检视;供试品色谱中,在与对照品色谱相应的位置上,显相同颜色的荧光斑点。
一种无糖型消银颗粒的质量检测方法,苦参碱的含量测定方法为:
取本品装量差异项下的内容物,研磨成粉末,取7g,精密称定,置于有塞的锥形瓶中,加入50ml氯仿,5ml浓氨试液,水浴加热回流1小时,冷却后分取氯仿液,加入氯仿30ml于残渣中,加热回流2次,每次30分钟,合并氯仿液,回收氯仿,残渣用无水乙醇分次溶解、洗涤,定量转移至5ml量瓶中,稀释至刻度,摇匀,作为供试品溶液;另取苦参碱对照品适量,精密称定,加无水乙醇制成每1ml含1mg苦参碱的溶液,作为对照品溶液;对照薄层色谱法试验,精密吸取上述两种溶液各4μL,分别交叉点于同一硅胶G薄层板上,以环己烷-氯仿-甲醇-浓氨试液比例为25:50:6:2的下层溶液为展开剂,在氨蒸气饱和下展开,取出后晾干,喷涂稀碘化铋钾试液,在薄层板上覆盖同样大小的玻璃板,周围用胶布固定,放置60分钟,对照薄层色谱法进行扫描,波长:λs=500nm,λR=650nm,测量供试品吸收度积分值与对照品吸收度积分值,计算结果;
本品每袋含苦参以苦参碱(C15H24N2O)计,不得少于2.1mg。
以实施例1制得的无糖型消银颗粒为例对其效果进行功效检测,选取100名患有血热风燥型白疵或者血虚风燥型白疵等症状中的一种或多种的高血糖、高血脂患者,其中男性57例,女性43例;年龄30-45岁,对患者进行一次5ml,一日2次持续15天的给药,86例患者症状明显改善。
对于实施例2、实施例3、实施例4和实施例5中提供的临床实验结果与实施例1的实验结果类似,对于皮疹为点滴状,基底鲜红色,表面覆有银白色鳞屑,或皮疹表面覆有较厚的银白色鳞屑,较干燥,基地淡红色瘙痒较甚等症状均具有良好的治疗效果且无副反应的情况出现。
本领域技术人员在考虑说明书及实践这里公开的发明后,将容易想到本发明的其它实施方案。本申请旨在涵盖本发明的任何变型、用途或者适应性变化,这些变型、用途或者适应性变化遵循本发明的一般性原理并包括本发明未公开的本技术领域中的公知常识或惯用技术手段。说明书和实施例仅被视为示例性的,本发明的真正范围和精神由下面的权利要求指出。
应当理解的是,本发明并不局限于上面的描述,并且可以在不脱离其范围进行各种修改和改变。本发明的范围仅由所附的权利要求来限制。
Claims (5)
1.一种无糖型消银颗粒,其特征在于,所述无糖型消银颗粒由如下重量份的原料药组成:地黄182,牡丹皮92,赤芍92,当归92,苦参92,金银花92,玄参92,牛蒡子92,蝉蜕46,白鲜皮92,防风46,大青叶92,红花46,无糖型辅料450~600,非糖调味剂;按照如下方法制备成无糖型颗粒:
将金银花、红花粉碎成细粉;地黄、牡丹皮、赤芍、当归、苦参、玄参、牛蒡子、蝉蜕、白鲜皮、防风和大青叶酌予碎断,加七倍量70%乙醇浸渍12小时,滤过,再加70%乙醇,回流提取12小时,滤过,合并提取液,回收乙醇至无醇味,浓缩成稠膏,加入金银花、红花细粉,混匀,低温干燥,粉碎成细粉,加辅料、调味剂,混匀,制成颗粒,干燥。
2.根据权利要求1所述的无糖型消银颗粒,其特征在于,所述无糖型辅料包括淀粉、木糖醇、微晶纤维素、乳糖或者甘露醇。
3.根据权利要求1或2所述的无糖型消银颗粒,其特征在于,所述调味剂包括安赛蜜、甜蜜素、阿斯巴甜或者甜菊苷。
4.一种无糖型消银颗粒的质量检测方法,其特征在于,鉴别方法包括以下项目的部分或全部:
(1):取本品10g,研磨成粉末,加入40ml氯仿,加热回流20分钟,放置冷却后过滤,滤液浓缩至1ml,作为供试品溶液;另取靛玉红、苦参碱对照品,分别加氯仿制成每1ml各含1mg的靛玉红、苦参碱溶液,作为对照品溶液;对照薄层色谱法试验,吸取供试品溶液10~20μL、对照品溶液各5μL,分别点于同一硅胶G薄层板上,以苯-丙酮-甲醇的比例为8:3:0.5为展开剂,在氨蒸气饱和的展开缸内展开,取出后晾干;供试品色谱中,在与靛玉红对照品色谱相应的位置上,显相同颜色的斑点;再喷以改良碘化铋钾溶液,供试品色谱中,在与苦参碱对照品色谱相应的位置上,显示相同颜色的斑点;
(2):取本品10g,研磨成粉末,加入40ml乙醇,超声处理30分钟,过滤后将滤液蒸干,加入15ml水使残渣溶解,过滤,滤液用乙醚提取2次,每次15ml,弃去乙醚液,用水饱和正丁醇提取3次,每次15ml,合并正丁醇液,蒸干,加入1ml乙醇使残渣溶解,作为供试品溶液;另取芍药苷对照品,加乙醇制成每1ml含1mg的芍药苷溶液,作为对照品溶液;对照薄层色谱法试验,吸取上述两种溶液各5~10μL,分别点于同一硅胶G薄层板上,以氯仿-醋酸乙酯-甲醇-甲酸比例为40:5:10:0.2为展开剂展开,取出后晾干,喷以5%香草醛硫酸溶液,热风吹至斑点显色清晰;供试品色谱中,在与对照色谱相应的位置上,显相同颜色的斑点;
(3)取本品5g,研磨成粉末,加入12ml丙酮、3ml水,振摇5分钟,浸泡5分钟,过滤后滤液作为供试品溶液;另取红花对照药材0.2g,同法制成对照药材溶液;对照薄层色谱法试验,吸取上述两种溶液各5μL,分别点于同一硅胶G薄层板上,以醋酸乙酯-甲酸-水-甲醇比例为7:2:3:0.3为展开剂展开,取出后晾干;供试品色谱中,在与对照药材色谱相应的位置上,显相同的红色斑点;
(4):取本品10g,加入40ml乙醇,加热回流1小时,过滤后滤液蒸干,加入5ml水使残渣溶解,浸泡30分钟,过滤后滤液分别用10ml和5ml醋酸乙酯提取2次,合并醋酸乙酯液,蒸干,加入1ml甲醇使滤渣溶解,作为供试品溶液;另取绿原酸对照品,加甲醇制成每1ml含0.5mg的绿原酸溶液,作为对照品溶液;对照薄层色谱法试验,吸取上述两种溶液各1μL,分别点于同一聚酰胺薄膜上,以冰醋酸-水比例为1:2为展开剂展开,取出后晾干,置于365nm的紫外灯下检视;供试品色谱中,在与对照品色谱相应的位置上,显相同颜色的荧光斑点。
5.如权利要求4中所述的一种无糖型消银颗粒的质量检测方法,其特征在于,苦参碱的含量测定方法为:
取本品装量差异项下的内容物,研磨成粉末,取7g,精密称定,置于有塞的锥形瓶中,加入50ml氯仿,5ml浓氨试液,水浴加热回流1小时,冷却后分取氯仿液,加入氯仿30ml于残渣中,加热回流2次,每次30分钟,合并氯仿液,回收氯仿,残渣用无水乙醇分次溶解、洗涤,定量转移至5ml量瓶中,稀释至刻度,摇匀,作为供试品溶液;另取苦参碱对照品适量,精密称定,加无水乙醇制成每1ml含1mg苦参碱的溶液,作为对照品溶液;对照薄层色谱法试验,精密吸取上述两种溶液各4μL,分别交叉点于同一硅胶G薄层板上,以环己烷-氯仿-甲醇-浓氨试液比例为25:50:6:2的下层溶液为展开剂,在氨蒸气饱和下展开,取出后晾干,喷涂稀碘化铋钾试液,在薄层板上覆盖同样大小的玻璃板,周围用胶布固定,放置60分钟,对照薄层色谱法进行扫描,波长:λs=500nm,λR=650nm,测量供试品吸收度积分值与对照品吸收度积分值,计算结果;
本品每袋含苦参以苦参碱(C15H24N2O)计,不得少于2.1mg。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201611090054.7A CN106361884A (zh) | 2016-11-28 | 2016-11-28 | 无糖型消银颗粒及其质量检测方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201611090054.7A CN106361884A (zh) | 2016-11-28 | 2016-11-28 | 无糖型消银颗粒及其质量检测方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN106361884A true CN106361884A (zh) | 2017-02-01 |
Family
ID=57892478
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201611090054.7A Pending CN106361884A (zh) | 2016-11-28 | 2016-11-28 | 无糖型消银颗粒及其质量检测方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN106361884A (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114984115A (zh) * | 2022-07-11 | 2022-09-02 | 陕西康惠制药股份有限公司 | 一种消银颗粒中药组合物的制备方法 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1528416A (zh) * | 2003-10-17 | 2004-09-15 | 陕西康惠制药有限公司 | 治疗银屑病的颗粒及其制备工艺 |
CN1689636A (zh) * | 2004-04-07 | 2005-11-02 | 北京奇源益德药物研究所 | 以丹参和红花制成的中药注射剂的质量控制方法 |
CN101199663A (zh) * | 2006-12-14 | 2008-06-18 | 黑龙江福和华星制药集团股份有限公司 | 治疗银屑病的中药及其制备方法 |
CN101647903A (zh) * | 2008-08-13 | 2010-02-17 | 黑龙江福和华星制药集团股份有限公司 | 一种治疗银屑病的中药的质量标准 |
CN102590433A (zh) * | 2012-02-28 | 2012-07-18 | 山东阿如拉药物研究开发有限公司 | 一种肝畅制剂的质量检测方法 |
-
2016
- 2016-11-28 CN CN201611090054.7A patent/CN106361884A/zh active Pending
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1528416A (zh) * | 2003-10-17 | 2004-09-15 | 陕西康惠制药有限公司 | 治疗银屑病的颗粒及其制备工艺 |
CN1689636A (zh) * | 2004-04-07 | 2005-11-02 | 北京奇源益德药物研究所 | 以丹参和红花制成的中药注射剂的质量控制方法 |
CN101199663A (zh) * | 2006-12-14 | 2008-06-18 | 黑龙江福和华星制药集团股份有限公司 | 治疗银屑病的中药及其制备方法 |
CN101647903A (zh) * | 2008-08-13 | 2010-02-17 | 黑龙江福和华星制药集团股份有限公司 | 一种治疗银屑病的中药的质量标准 |
CN102590433A (zh) * | 2012-02-28 | 2012-07-18 | 山东阿如拉药物研究开发有限公司 | 一种肝畅制剂的质量检测方法 |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114984115A (zh) * | 2022-07-11 | 2022-09-02 | 陕西康惠制药股份有限公司 | 一种消银颗粒中药组合物的制备方法 |
CN114984115B (zh) * | 2022-07-11 | 2023-05-26 | 陕西康惠制药股份有限公司 | 一种消银颗粒中药组合物的制备方法 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101856449A (zh) | 一种清热利湿,活血通淋中药组合物及制备方法和质量检测方法 | |
CN101011527B (zh) | 一种橘红丸的改型制剂及其制备方法 | |
CN100496555C (zh) | 解毒止痒中药组合物及其制备方法 | |
CN101366876A (zh) | 一种治疗咽喉肿痛的中药制剂及其制备方法 | |
CN101385819A (zh) | 一种治疗痔疮的药物及其制剂的制备方法 | |
CN107102093B (zh) | 复方丹茵膏的检测方法 | |
CN101269182B (zh) | 一种治疗小儿风热感冒的药物组合物 | |
CN101195007B (zh) | 一种治疗感冒咳嗽的药物及其制剂的制备方法及质量控制方法 | |
CN101336986B (zh) | 一种药物组合物的检测方法 | |
CN1887324B (zh) | 一种治疗肝肾不足的中药组合物及其制备方法和分析方法 | |
CN1806832B (zh) | 一种药物组合物及其制备方法和质量检测方法 | |
CN106361884A (zh) | 无糖型消银颗粒及其质量检测方法 | |
CN106389562A (zh) | 一种蒲地蓝消炎颗粒及其制备方法和产品质量控制方法 | |
CN101879271B (zh) | 橘红胶囊的质量检测方法 | |
CN101274034B (zh) | 一种具有疏风解表、清热解毒作用的中药组合物 | |
CN102274332B (zh) | 治疗消化性溃疡的中药散剂的制备工艺 | |
CN101869675B (zh) | 一种治疗暑湿感冒的中药组合物颗粒剂及其制备方法 | |
CN101485779B (zh) | 一种治疗银屑病的药物组合物及制备方法和质量检测方法 | |
CN105477361B (zh) | 一种治疗胃炎的中药组合物制备方法及制剂 | |
CN107014945B (zh) | 一种治疗急性传染性肝炎的中药制剂的检测方法 | |
CN101269175A (zh) | 痔舒适洗液的质量控制方法 | |
CN105477360B (zh) | 一种治疗胃炎的中药组合物制备方法及制剂 | |
CN101073611B (zh) | 一种抗肿瘤的药物组合物 | |
CN105395889B (zh) | 一种治疗胃炎的中药组合物制备方法及制剂 | |
CN101947278B (zh) | 一种治疗病毒性下呼吸道感染的中药及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20170201 |
|
RJ01 | Rejection of invention patent application after publication |